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Abstract 
Propranolol, a widely used beta-blocker, inhibits the hydrolysis reaction of enzyme choli-
nesterase. Measurements of the difference in rate of hydrolysis rate between uninhibited
and inhibited reactions allow the development of a kinetic method for its determination.
Both systems, enzyme–substrate–chromogen and enzyme–substrate–chromogen–inhibi-
tor, were characterized through biochemical kinetic parameters (KM, 0.326–0.330 mmol/L; 
Vmax , 40.0–43.0 μmol/Lmin). The inhibition type was recognized as competitive and the
inhibition constant, Ki, was determined to be 22.60 μmol/L. The detection and quantifica-
tion limits were calculated as 0.004 and 0.0136 μmol/L, respectively. Accuracy and pre-
cision of proposed methods were tested. The proposed method showed good sensitivity,
selectivity, simplicity and rapidity, thus it is convenient for clinical applications. 
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Propranolol ((t)-isopropylamino-3-(1-naphthyloxy 
propan-2-ol) hydrochloride, PPH) is a widely prescribed 
drug in treatment of hypertension, angina pectoris, car-
diac arrhythmia and hyperthyroidism. It belongs to a 
group of non-selective β-blockers, expressed with mo-
derate intrinsic sympathetic mimetic activity. The re-
lationship between the propranolol concentration in 
patients’ blood and its pharmacological action is not 
always possible to establish, so that the dosage of the 
drug is determined by heart rate following and blood 
pressure measurements [1]. Regarding that fact, the 
determination of propranolol amounts in patients’ 
blood is herein not of essential significance, but still, it 
is very important to monitor the quality of pharmaco-
logical preparations of propranolol hydrochloride, its 
content in effluents and finally in forensic samples. 
A variety of methods was developed and validated 
for propranolol determination in samples of different 
origin. In the following review of the existing methods 
for propranolol determination, special attention will be 
devoted to the methods applied in pharmaceutical 
preparations and effluents (Table 1). 
Numerous spectrophotometric methods give the 
opportunity to determine propranolol in pharmaceuti-
cal samples in various ranges, that can be generalized 
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as from 0 to 20 mmol/L, while the other methods offer 
even more wide interval of determination (from 0 to 
96.4 mmol/L [33]). Some of the methods are applied in 
nanomolar concentration intervals, though their low 
operational range or sensitivity is not really of substan-
tial importance, having in mind the macroscopic nature 
of pharmaceutical or environmental samples. The main 
issue can be availability of the proposed assay, con-
sidering instruments and reagent, time spare and of 
course reliability. The high selectivity, short analysis 
time, simplicity are desirable as well as wide operatio-
nal range. 
Working on cholinesterase inhibition analytical stu-
dies [35,36], and taking into consideration the presence 
of amino group in the molecule of propranolol (Figure 
1) and literature data [37], the idea of developing an 
enzyme inhibition based assay emerged. The inhibiting 
effect of propranolol on serum cholinesterase was ap-
plied to a new kinetic enzyme method for its determi-
nation. Kinetic methods of analysis have the general 
advantage of combining high sensitivity, good selecti-
vity with relatively simple, rapid procedures and inex-
pensive instruments, such as spectrophotometers. High 
specificity of the enzymatic reactions enabled usage 
pooled human serum as a source of cholinesterase. 
Modified Ellman’s method [36] was applied for reaction 
rate monitoring. In that way, biochemical reaction and 
inhibition parameters were determined in common cli-
nical biochemical laboratory conditions, without enga-
gement of expensive instruments and reagents or using 
complex procedures. The proposed method was vali-
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dated in accordance with modern analytical demands 
(selectivity, sensitivity, linearity, accuracy, precision etc.). 
EXPERIMENTAL 
All used chemicals and reagents were p.a. grade. 
Propranolol hydrochloride (PPH, purity > 99%) was kindly 
provided by Galenika AD, Belgrade; stock solution was 
of 10 mg/mL in deionized water. Working solutions 
were prepared daily, by dilution of the stock solution. 
Buthyrylthiocholine iodide (BUTC, purity > 99%), 5,5'- 
-dithiobis(2-nitrobenzoic acid) (DTNB) were purchased 
from Sigma, Germany. BUTC stock solution was of 
133.33 mmol/L. DTNB stock solution was prepared by 
Table 1. A review of the methods for propranolol determination in the pharmaceuticals
Method Range of determination, μmol/L Sample Reference
Spectrophotometric determinations 
With Ce(SO4)2 0–16.90 Bulk drug, tablets [2] 
With metavanadate 0–13.52 Tablets [3] 
Bromate/bromide mixture, methyl orange 1.69–169.03 Tablets [4] 
Hg(SCN)2, Fe
3+ as indicator 33.81–169.03 Bulk drug, tablets [5] 
Nitration of propranolol with uranyl nitrate and 
thorium nitrate in H2SO4 
6.76–108.18 Pure form, pharmaceutical 
preparation 
[6] 
Propranolol oxidation by known excess of 
N-bromosuccinimide 
1.69–42.26 Dosage forms [7] 
Reaction of propranolol with sigma-acceptor iodine 
and pi-acceptors 
13.52–405.68 Pure form, pharmaceutical 
formulation 
[8] 
With diazotized 4-amino-3,5-dinitrobenzoic acid 3.38–27.05 Tablets [9] 
Excess of  N-bromosuccinimide +dye celestine blue 0.676–16.903 Pharmaceutical formulation [10] 
KNO3 + H2SO4 (+ alkaline NaOH and urea) 1.08–405.68 Pharmaceuticals [11] 
NaNO2 + K2SO4 6.76–169.03 Dosage forms [12] 
Dissolution in isopropanol, addition of Ag2O + 
10% CH3CHO and 10% chloranil 
16.90–202.84 Bulk tablets [13] 
With brom thymol blue 3.00–25.00 Bulk tablets [14] 
With 2,4 dinitro-1-fluorobenzene 16.90–101.42 Tablets [15] 
Complex formation with Cu(II) and Co(II) 20–20000 Dosage forms [16] 
Other methods 
Differential pulse polarography 0.50–50.00 Tablets [17] 
Cyclic voltametry and pulse voltametry 1–20 Spiked water samples [18] 
Phosphorimetric 0–1.69 Pharmaceutical preparations [19] 
AAS (chelation with Cu(II) ion) 0–135.23 Pharmaceutical preparations [20] 
Indirect AAS method 4.54–346.98 Water solutions, tablets [21] 
Spectrofluorimetry 0.08–0.68 Tablets, injections [22] 
Spectrofluorimetry 0.023–0.771 Pharmaceutical formulations [23] 
Spectrofluorimetry 0.077–3.856 Urine, pharmaceutical 
preparations 
[24] 
SIA with fluorescence detection 0–15.423 Tablets [25] 
Chemiluminometry 77.115–578.363 Pharmaceutical preparations [26] 
FIA with fluorescence detection 0–0.001 Pharmaceutical preparations, 
urine 
[27] 
FIA with chemiluminiscence detection 3.855–77.100 Pharmaceutical formulations [28] 
FIA with chemiluminiscence detection 3.855–67.462 Pharmaceutical preparations [29] 
Kinetic-potentiometric 100–1000 Commercial formulations [30] 
Miccelar stabilized room temperature 
phosphorescence 
0.096–1.536 Commercial formulations, urine [31] 
Potentiometric sensors 0.1–10000 Dosage forms [32] 
LC 3.856–96.400 Pharmaceutical formulations [33] 
SPE-LC-ESI/MS 0.00068–0.02197 Hospital effluent wastewaters [34] 
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dissolving the exact weighted mass (0.0792 g) in 5 mL 
of phosphate buffer pH 7.4, followed by addition of 60 
mg of NaHCO3, and dilution to 10 mL in the volumetric 
flask. NaHCO3, KH2PO4, Na2HPO4, used for the buffers 
preparation, were from Merck, Germany. 
N
H
HCl
O
 
Figure 1. Structural formula of propranolol hydrochloride. 
For solutions preparation and for final dishes wash-
ing, deionized water (conductivity < 1μS, MicroMed 
high purity water system, TKA Wasseraufbereitungs-
systeme GmbH) was used. 
All concentrations described here are the initial 
concentrations in the reaction mixture at time zero 
after mixing.  
A Konelab 20 analyzer (Thermo Scientific), with flow 
thermostated cells, length 7 mm, λ = 405 nm was used 
for spectrophotometric measurements. The main ad-
vantage of the Konelab 20 analyzer is its use of very 
small volumes of reagents (the volume of the mea-
suring probe is 200 μL), though the possibility of per-
forming about 40 analyses per hour is not negligible 
either. 
Ten healthy volunteers (18–65 years old from both 
sexes) donated their blood with written consent, which 
was used for serum preparation in the Pirot General 
Hospital. Each of the volunteers had neither recent nor 
past history of significant medical disorder, as well as 
drug, cigarette or alcohol abuse. For at least a month 
before blood donation, none of the volunteers had 
been taking any medication. A 5 mL blood sample was 
collected from each donator in a vacutainer tube, cen-
trifuged for 10 min at 3000 rpm, after which the serum 
supernatants were collected, mixed and used for the 
enzyme assay. The hydrolysis reaction of butyrylthio-
choline to thiocholine is catalyzed by serum cholineste-
rase; the product reacts with DTNB forming colored 
compound (5-thio-2-nitrobenzoic acid); the reaction 
rate is determined from the increase of color, mea-
sured at 405 nm, in 6 cycles of 28 s and thermostated 
at 310 K. 
Solutions of propranolol (10 μL) were mixed with 
serum diluted with the phosphate buffer in ratio 1:9, 
v/v (10 μL), the phosphate buffer solution (160 μL) and 
preincubated 10 min (at 310 K); DTNB solution (10 μL) 
was added and left for 60 s; substrate solution (BUTC, 
10 μL) was added. The same procedure was applied for 
analysis of samples. The obtained kinetic data were 
interpreted by tangent method. Each kinetic result is 
the average of five determinations. 
Twenty tablets of every pharmaceutical preparation 
was taken and ground into a fine powder. Mass of the 
powder equivalent to 100 mg of PPH was exactly 
weighed and transferred into a 100 mL calibrated flask. 
About 60 ml of water was added and the content was 
vigorously shaken. The contents were filtered using a 
quantitative filter paper into the 100 mL volumetric 
flask and diluted to the mark. An appropriate volume of 
the stock solution was used for analysis.  
RESULTS AND DISCUSSION 
The main parameters affecting the performance of 
the proposed method were studied to determine the 
optimal working configuration. These parameters were 
optimized by the invariant method, i.e., each parame-
ter was optimized by setting the other parameters to 
be constant. To determine the kinetic biochemical pa-
rameters, the dependence of reaction rate on substrate 
(butyrylthiocholine) concentration was estimated for 
the range 0.208–6.650 mmol/L. The methods of Line-
weaver-Burk, Eadie–Hofstee and Hanes linearization, 
resulted with the similar values for Michaelis-Menten’s 
constant (0.330, 0.305 and 0.326 mmol/L, respectively) 
and also for Vmax (42.29, 40.00 and 42.38 μmol/L, res-
pectively). The obtained kinetic data enable conclusion 
that the PPH and serum cholinesterase interact in the 
competitive inhibition manner. Once the mechanism of 
inhibition was established, the inhibition constant was 
calculated from the function of the inhibition reaction 
rate depending of different PPH concentrations. Di-
xon’s method was applied for inhibition constant deter-
mination, which was found to be 2.71 μmol/L. 
Different PPH concentrations affect relative enzyme 
activity of the serum cholinesterase in the manner 
shown in Figure 2. At PPH concentration of 169.03 
μmol/L, the enzyme is almost completely inhibited. The 
IC50 value was determined as 22.60 μmol/L. The inter-
val of relative enzyme activity higher than 48.35% was 
applied for the development of method for PPH deter-
mination. 
The dependences of reaction rates on pH for reac-
tion without/with inhibitor are shown in Figure 3. The 
pH 7.6 was chosen as optimal, because that pH value 
gave the greatest difference for basic and inhibitor 
reaction rates. 
Six substrate (butyrylthiocholine iodide) concentra-
tions (0.208, 0.416, 0.833, 1.667, 3.334 and 6.665 
mmol/L) were used for the estimation of the reaction 
rates for reaction without/with different PPH concen-
trations (Figure 4). The substrate concentration 1.667 
mmol/L was chosen as optimal, because that value 
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gave the maximal difference in the basic and inhibitor 
reaction rates. 
The differential variant of tangent method [38] was 
applied for the construction of calibration graph, under 
optimal conditions (pH 7.6; c(buffer) = 100 mmol; 
c(butyrylthioholine iodide) = 1.667 mmol/L; T = 310 K). 
The linear relationship between the slope (tan α) and 
PPH concentrations in the range 0.082–21.120 μmol/L 
(in probe) was established. The equation used for the 
calibaration graph was: 
tan α×100 = (21.2853±0.0871) – (0.4937±0.0107)c (1)  
where c is expressed in μmol/L and R = –0.99836. 
The limit of detection (LOD) and limit of quantifi-
cation (LOQ) were calculated applying formulas 3SDB/m 
and 10SDB/m respectively (where SDB is standard devi-
ation of the blank signal and m has a definite value 
when the intercept of the calibration graph is zero or 
virtually zero [39] and they were 0.004 and 0.0136 
μmol/L, respectively. Five replicate experiments for the 
blank and three concentrations of PPH were conducted 
for precision and accuracy estimation of the proposed 
method and the results are shown in Table 2.  
By applying the calibration graph, it is possible to 
determine propranolol from different samples in the 
range 1.65–422.40 μmol/L. 
 
Figure 2. Function of relative activity of serum cholinesterase on concentration of propranolol (PPH). 
 
Figure 3. The dependence of the reaction rate in absence of PPH (1) and in presence of PPH (2,3) on pH. Conditions: 
c(BUTC) = 1.667 mmol/L; c(phosphate buffer) = 100 mmol/L; 2-c(PPH) = 2.637 μmol/L; 3-c(PPH) = 21.129 μmol/L); T = 310 K. 
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In order to examine the impact of possible interfe-
rences, the influence of the most common filling sub-
stances (calciumcarboxymethylcellulose, carmine, gela-
tin, glycerol, lactose, magnesium carbonate, magne-
sium stearate, methylhydroxypropylcellulose and TiO2) 
was tested on the inhibitor reaction rate. The potential 
interfering substances were taken in excess and pre-
pared in the same way as pharmaceutical samples. 
Regarding the 2SD criteria [40] at constant propranolol 
concentration in the probe of 10.56 μmol/L, none of 
the potential interferences showed measurable influ-
ence on the inhibitor reaction rate, in the double ratio 
that exists in pharmaceutical formulations. 
 
The proposed method was applied for PPH deter-
mination in tablets of different origin. Results were 
validated by standard addition method (Table 3). 
CONCLUSION 
The known fact that propranolol inhibits human 
serum cholinesterase activity was confirmed and ki-
netic biochemical parameters were established. On 
that basis, the competitive type of inhibition was pro-
posed, which can be justified by the existence of charge 
depolarization in the propranolol hydrochloride mole-
cule, which can be very well fitted in the active site of 
the enzyme very similar to the acylcholine esters. Con-
 
Figure 4. The dependence of the reaction rate without (1) and with PPH at different concentrations (2–1.318, 3–5.282 and 4–21.129 
μmol/L) on buthyrylthiocholine concentration; c(buffer) = 100 mmol/L, pH 7.6; T = 310 K. 
Table 2. Precision (presented as RSD %) and accuracy (presented as Recovery %) of the proposed method; the concentrations 
present averages of five determinations ± standard deviation ( x ± SD) 
c(PPH) in probe 
(measured), μmol/L 
c(PPH) in the initial 
solution(measured), μmol/L 
c(PPH) in probe (found), 
μmol/L, x ± SD 
c(PPH) in the initial solution 
(found), mmol/L, x ± SD RSD / % Recovery, %
0.659 13.180 0.666±0.023 13.328±0.462 3.47 101.06 
2.637 52.740 2.668±0.083 53.352±1.655 3.10 101.17 
10.565 211.300 10.697±0.15 211.300±3.093 1.45 101.46 
      
Table 3. Precision (RSD) and accuracy (standard addition method) test of PPH determination in tablets. Results are expressed as 
average of five replicate ( x ± SD) experiments for different PPH concentrations 
Sample c(PPH)a, mg/tablet Found c(PPH)b, mg/tablet RSD / % Found c(PPH)c, mg/tablet Mean value of recovery, %
Propranolol tablets 40 39.89±0.60 1.50 40.21±0.56 100.15 
Inderal tablets 10 9.96±0.14 1.16 9.98±0.11 99.85 
Inderal tablets 40 39.77±0.60 1.52 39.86±1.17 99.64 
Inderal tablets 80 79.75±1.25 1.57 79.87±0.88 99.84 
aLabeled by manufacturer; bcalibration graph; cstandard addition method 
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firming and characterizing the inhibition enabled the 
possibility of development of a new enzymatic kinetic 
assay for propranolol determination.  
Methods for quantification of propranolol are cru-
cial in determining the quality of pharmacological pre-
parations. The proposed method, with its broad deter-
mination interval, excellent sensitivity, simplicity, re-
producibility, precision, accuracy and selectivity, satis-
fies all the requirements for practical application. In 
addition, the equipment used for its implementation is 
available to any clinical laboratory, which greatly con-
tributes to the availability of the method. 
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IZVOD 
ENZIMSKA KINETIČKA METODA ZA ODREĐIVANJE PROPRANOLOL-HIDROHLORIDA U FARMACEUTSKIM 
PREPARATIMA ZASNOVANA NA NJEGOVOM INHIBITORSKOM DELOVANJU NA HOLINESTERAZU 
Vesna P. Stankov-Jovanović1, Violeta D. Mitić1, Marija D. Ilić1, Ljuba M. Mandić2, Snežana D. Nikolić-Mandić2 
1Univerzitet u Nišu, Prirodno–matematički fakultet, Niš, Srbija 
2Univerzitet u Beogradu, Hemijski fakultet, Beograd, Srbija 
(Naučni rad) 
Za propranolol, često propisivani neselektivni beta blokator, utvrđeno je da
inhibira reakciju enzimske hidrolize butiriltioholin-jodida, koja je katalizovana 
serumskom holinesterazom. Merenjem razlike u brzini osnovne i inhibitorske re-
akcije hidrolize u prisustvu propranolola kao inhibitora, moguće je razviti kinetičku
metodu za određivanje propranolola. Oba sistema, enzim–supstrat–hromogen 
kao i enzim–supstrat–hromogen–inhibitor okarakterisani su biohemijskim kinetič-
kim parametrima (KM, 0,326–0,330 mmol/L; Vmax, 40–42,99 μmol/L min), inhibicija 
je definisana kao kompetitivna i određena je konstanta inhibicije 22,60 μmol/L. Da 
bi se u potpunosti iskoristile sve mogućnosti predložene metode u pogledu oset-
ljivosti, tačnosti, preciznosti i selektivnosti, optimizovani su reakcioni uslovi. Kons-
truisana je kalibraciona prava, izračunata odgovarajuća jednačina i određeni gra-
nica detekcije i kvantifikacije, i to 0,004 i 0,0136 μmol/L, redom. Tačnost i preciz-
nost predložene metode su ispitane za tri koncentracije propranolola u oblasti
kalibracione prave (0,082–21,120 μmol/L) u pet ponavljanja. Takođe, ispitan je 
uticaj većeg broja supstanci koje se mogu naći u uzorku na brzinu reakcije. Opti-
mizovana metoda je primenjena za određivanje propranolola u farmaceutskim
preparatima. Tačnost predložene metode je ispitana primenom metode stan-
dardnog dodatka. Predložena metoda ima dobru osetljivost, selektivnost, jednos-
tavna je i brza, i nadasve lako dostupna, i na taj način primenljiva u velikom broju
laboratorija. 
  Ključne reči: Propranolol • Holinesteraza
• Kinetička metoda • Farmaceutski pre-
parati 
 
